Genmab — September 2020

[E_L]

If anyone is interested in a position as postdoctoral dara researcher with dr. Niels van Donk

• https://www.academictransfer.com/en/294131/postdoc-cancer-center-amsterdam/

[transalp]

Go morgen..

[Mcjean]

Maybe now E L from Genmabchat will join the adventure and use some of his huge energy in this stock, because now Qfuel arrive to netherland:-D

[E_L]

E L from Genmabchat thinks he missed that -plastic- boat But he says that if he can sell his Genmabs at 18.000 he may look into it again

[Mcjean]

Whole new business my friend, you better join

[Topo]

Jeg skylder sgu dig en øl for dit skriv om qfuel Mcjean

[StockBull]

https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/86671_Oct_8_target.JPG mulig kursudvikling kommende måned såfremt markedet opføre sig pænt

[Sukkeralf]

Just a moment...

(www.firstwordpharma.com)

[Sukkeralf]

test

[Sukkeralf]

The study found the addition of NINLARO to lenalidomide and dexamethasone resulted in a 13.5 month increase in median progression-free survival (PFS) (35.3 months in the NINLARO arm, compared to 21.8 months in the placebo arm

[Sukkeralf]

The trial did not meet the threshold for statistical significance and the primary endpoint of PFS was not met.

[E_L]

Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Light Chain (AL) Amyloidosis

[E_L]

Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Light Chain (AL) Amyloidosis

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA)...

(www.prnewswire.com)

[E_L]

The sBLA is being reviewed under the FDA Real-Time Oncology Review (RTOR) program,

[Sukkeralf]

wauu - nice

[Sukkeralf]

Lets beat the record time for approval please

[E_L]

[E_L]

ADC Therapeutics Announces Publication Highlighting the Potential of Camidanlumab Tesirine (Cami) as a Novel Immuno-oncology Approach for Solid Tumor Cancers
Preclinical study published in the Journal for ImmunoTherapy of Cancer supports continued evaluation of CD25-targeted ADC in Phase 1b clinical trial in selected advanced solid tumors https://www.businesswire.com/news/home/20200910005550/en/ADC-Therapeutics-Announces-Publication-Highlighting-Potential-Camidanlumab

[E_L]

The study evaluated the antitumor activity of a pyrrolobenzodiazepine (PBD) dimer-based, CD25-targeted ADC, either alone or in combination with a checkpoint inhibitor, in CD25-negative syngeneic colon cancer models that exhibit tumor infiltration of CD25-expressing regulatory T cells (Tregs).

[E_L]

Data demonstrated that single low doses of the CD25-targeted ADC resulted in potent and durable antitumor activity against established CD25-negative solid tumors with infiltrating Tregs, both as a monotherapy and in combination with an anti-PD1 checkpoint inhibitor.